<DOC>
	<DOCNO>NCT00338897</DOCNO>
	<brief_summary>The primary objective : - demonstrate efficacy SR123781A prevention venous thromboembolism ( VTE ) demonstration dose-response patient undergoing total hip replacement surgery . The secondary objective : - evaluate safety SR123781A prevention VTE elective total hip replacement surgery ; - ass SR123781A pharmacokinetic profile patient undergo elective total hip replacement surgery .</brief_summary>
	<brief_title>Dose Ranging Study Elective Total Hip Replacement Surgery</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<criteria>Patients schedule undergo elective total hip replacement surgery revision least one component total hip replacement perform &gt; 6 month prior study entry Pregnant nursing woman , woman childbearing potential use effective contraceptive method negative pregnancy test perform immediately randomization Known progressive malignant disease Ischemic stroke last 3 month Myocardial infarction ( MI ) last 3 month Any major orthopedic surgery 3 month prior study start Clinical sign symptom DVT PE within last 12 month symptom post phlebitic syndrome ( condition may confound DVT/PE assessment ) Treatment antithrombotic agent within 7 day prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Venous Thromboembolism</keyword>
	<keyword>Prevention</keyword>
	<keyword>Arthroplasty</keyword>
	<keyword>Replacement</keyword>
	<keyword>Hip</keyword>
	<keyword>orthopedic surgery</keyword>
</DOC>